Cadence Pharmaceuticals Completes Name Change and Launches Website.

SAN DIEGO -- Cadence Pharmaceuticals, Inc. (Cadence), a hospital-focused specialty pharmaceutical company, today announced that it has completed its name change from Strata Pharmaceuticals, Inc. and launched its website.

"Our new name connotes steady forward movement which characterizes the development of the both the Company and its products," said Ted Schroeder, President and Chief Executive Officer of Cadence. "The substantial progress we have made in executing our plan during the five months since we closed our first round of financing is reflected in our new identity."

The corporate website for Cadence can be found at http://www.cadencepharm.com. The site offers insight into the Company's strategy, management, and products, including the Phase III program for CPI-226, the Company's lead product candidate.

About Cadence Pharmaceuticals, Inc.

Cadence Pharmaceuticals, Inc. is a San Diego-based specialty pharmaceutical company focused on the development and commercialization of therapeutics utilized primarily in the hospital setting. The business of Cadence is driven by in-licensing and acquisition of late-stage development compounds and commercial-stage drugs. Cadence is backed by a syndicate of leading healthcare-focused venture capital firms, including Domain Associates, ProQuest Investments, and Windamere Venture Partners.

Cadence cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. The inclusion of forward-looking statements should not be regarded as a representation by Cadence that any of its plans will be achieved. Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in Cadence's business, including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, and producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization, or that could result in recalls or product liability claims; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. All forward-looking statements are qualified in their entirety by this cautionary statement and Cadence undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof.